Dimensional Fund Advisors LP reduced its stake in shares of K2M Group Holdings, Inc. (NASDAQ:KTWO) by 23.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,588 shares of the medical device company’s stock after selling 7,015 shares during the period. Dimensional Fund Advisors LP owned 0.05% of K2M Group worth $550,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. BNP Paribas Arbitrage SA raised its position in shares of K2M Group by 5,175.3% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock worth $109,000 after purchasing an additional 4,399 shares during the last quarter. Legal & General Group Plc raised its position in shares of K2M Group by 9.1% during the 1st quarter. Legal & General Group Plc now owns 6,763 shares of the medical device company’s stock worth $138,000 after purchasing an additional 564 shares during the last quarter. Dorsey & Whitney Trust CO LLC acquired a new position in shares of K2M Group during the 2nd quarter worth approximately $211,000. Symphony Asset Management LLC acquired a new position in shares of K2M Group during the 2nd quarter worth approximately $351,000. Finally, GSA Capital Partners LLP acquired a new position in shares of K2M Group during the 2nd quarter worth approximately $515,000. Hedge funds and other institutional investors own 99.16% of the company’s stock.
Shares of K2M Group Holdings, Inc. (KTWO) opened at $17.99 on Tuesday. The company has a current ratio of 3.06, a quick ratio of 1.67 and a debt-to-equity ratio of 0.29. K2M Group Holdings, Inc. has a twelve month low of $17.23 and a twelve month high of $25.99.
Several brokerages recently issued reports on KTWO. ValuEngine downgraded K2M Group from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Needham & Company LLC cut their price target on K2M Group from $27.00 to $26.00 and set a “strong-buy” rating for the company in a report on Thursday, November 2nd. Oppenheimer reiterated a “buy” rating and issued a $24.00 price target on shares of K2M Group in a report on Friday, November 10th. William Blair reiterated an “outperform” rating on shares of K2M Group in a report on Tuesday, October 10th. Finally, Cowen reiterated an “outperform” rating and issued a $22.00 price target (down from $28.00) on shares of K2M Group in a report on Tuesday, October 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $25.00.
K2M Group Company Profile
K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.
Want to see what other hedge funds are holding KTWO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for K2M Group Holdings, Inc. (NASDAQ:KTWO).
Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.